Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

PHASE2TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions
Primary Insomnia
Interventions
DRUG

Adipiplon

bilayer tablets 6 mg

DRUG

Placebo

Placebo

DRUG

Ambien CR

Ambien CR 12.5 mg

DRUG

Adipiplon

bilayer tablets 9 mg

Trial Locations (9)

10019

Clinilabs, Inc., New York

30342

Neurotrials Research, Inc, Atlanta

33026

Broward Research Group, Pembroke Pines

33143

Miami Research Associates, South Miami

45246

Tri-State Sleep Disorders Center, Cincinnati

60061

Sleep and Behavior Medicine Institute, Vernon Hills

63017

St. Luke's Hospital Sleep Medicine and Research Center, Chesterfield

66212

Vince & Associates Clinical Research, Overland Park

73112

Lynn Health Science Institute, Oklahoma City

Sponsors
All Listed Sponsors
lead

Neurogen Corporation

INDUSTRY